US 11364228
Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
granted A61KA61K31/437A61P
Quick answer
US patent 11364228 (Gaboxadol for therapeutic treatment of 1p36 deletion syndrome) held by OVID THERAPEUTICS INC. expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- OVID THERAPEUTICS INC.
- Grant date
- Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K31/437, A61P, A61P25/00, A61P25/14